Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant

A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant

The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.

Inclusion Criteria:

• BMI 27 to 40 kg/m^2
• Estimated glomerular filtration rate (eGFR) >/= 90 mL/min/1.73 m^2
• HbA1c < 6.0% and FPG < 6.7 mol/L

Exclusion Criteria:

• Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being
• History of Type 1 or Type 2 Diabetes
• History of, or currently has, acute or chronic pancreatitis or has triglyceride concentrations ≥500 mg/dL
• Has medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN II) or a family history of MTC or MEN II
• Current or past exposure to exenatide